Xynomic Pharmaceuticals, Inc. Report issue

For profit Phase 1 Phase 2 Phase 3
Founded: Shanghai China (2017)
Status: No NME R&D (2017)

Organization Overview

First Clinical Trial
2018
NCT03592472
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

Xynomic Pharmaceuticals, Inc.